(S)-N-[[3-[3-fluoro-4-[4-carbobenzoxypiperazin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide | 174649-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (S)-N-[[3-[3-fluoro-4-[4-carbobenzoxypiperazin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide
• 英文别名: benzyl 4-(4-{(5S)-5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl}-2-fluorophenyl)-1-piperazinecarboxylate；benzyl 4-[4-[(5S)-5-[(1,3-dioxoisoindol-2-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenyl]piperazine-1-carboxylate
• CAS: 174649-05-9
• 化学式: C₃₀H₂₇FN₄O₆
• 分子量: 558.566
• InChiKey: XIFWGKOTCLDCLY-JOCHJYFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  41
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  99.7
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (S)-N-[[3-[3-fluoro-4-[4-carbobenzoxypiperazin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide 在 palladium on activated charcoal 吡啶 、 二氯甲烷 、 氢气 、 三乙胺 、 甲胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 11.0h， 生成 N-[[(5S)-3-[3-氟-4-[4-(2-羟基乙酰基)-1-哌嗪基]苯基]-2-氧代-5-噁唑烷基]甲基]-乙酰胺
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections

  摘要：

  Bacterial resistance development has become a very serious clinical problem for many classes of antibiotics. The 3-aryl-2-oxazolidinones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action which involves very early inhibition of bacterial protein synthesis. We have prepared two potent, synthetic oxazolidinones, U-100592 and U-100766, which are currently in clinical development for the treatment of serious multidrug-resistant Gram-positive bacterial infections caused by strains of staphylococci, streptococci, and enterococci. The in vitro and in vivo (po and iv) activities of U-100592 and U-100766 against representative strains are similar to those of vancomycin. U-100592 and U-100766 demonstrate potent in vitro activity against Mycobacterium tuberculosis. A novel and practical asymmetric synthesis of (5S)-(acetamidomethyl)-2-oxazolidinones has been developed and is employed for the synthesis of U-100592 and U-100766. This involves the reaction of N-lithioarylcarbamates with (R)-glycidyl butyrate, resulting in excellent yields and high enantiomeric purity of the intermediate (R)-5-(hydroxymethyl)-2-oxazolidinones,

  DOI：

  10.1021/jm9509556
• 作为产物：
  描述：

  1-(2-氟-4-硝基苯基)哌嗪 在 正丁基锂 、 palladium on activated charcoal 、 氢气 、 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 丙酮 、 乙腈 为溶剂， 生成 (S)-N-[[3-[3-fluoro-4-[4-carbobenzoxypiperazin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide
  参考文献：
  名称：

  [EN] DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME
  [FR] MÉDICAMENTS CONJUGUÉS À DU PHOSPHATE D'HEXOSE ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION

  摘要：

  一种药物结合物、组合物和方法，通过将抗微生物药物与非代谢六糖磷酸酯结合，通过六糖磷酸转运体（UhpT）传递活性抗微生物药物，基于现有抗生素。还公开了联合给予抗生素和非代谢六糖磷酸酯作为抗微生物药物的方法。非代谢六糖磷酸酯可以构成性地和强烈地诱导UhpT的表达，从而显著提高抗生素的功效和/或抗微生物谱。这种药物结合物、组合物和方法将允许重复使用许多已被FDA批准但由于当前低功效和/或病原体对这些抗生素的抗药性而被放弃或停用的抗生素。

  公开号：

  WO2022072425A1

文献信息

• Discovery of a novel nitroimidazolyl–oxazolidinone hybrid with potent anti Gram-positive activity: Synthesis and antibacterial evaluation
  作者：Ali Khalaj、Maryam Nakhjiri、Amir Soheil Negahbani、Marjaneh Samadizadeh、Loghman Firoozpour、Saeed Rajabalian、Nasrin Samadi、Mohammad Ali Faramarzi、Neda Adibpour、Abbas Shafiee、Alireza Foroumadi

  DOI：10.1016/j.ejmech.2010.10.015

  日期：2011.1

  A number of linezolid analogues containing a nitroaryl-1,3,4-thiadiazole moiety, were prepared and evaluated as antibacterial agents against a panel of Gram-positive and Gram-negative bacteria. Among synthesized compounds, nitrofuran analogue 1b exhibited more potent inhibitory activity, with respect to other synthesized compounds and reference drug linezolid. The target compounds were also assessed for their cytotoxic activity against normal mouse fibroblast (NIH/3T3) cells using MTT assay. The results indicated that compound 1c exhibit potent antibacterial activity against Gram-positive bacteria at non-cytotoxic concentrations. (C) 2010 Elsevier Masson SAS. All rights reserved.
• An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants
  作者：Wanida Phetsang、Mark A.T. Blaskovich、Mark S. Butler、Johnny X. Huang、Johannes Zuegg、Sreeman K. Mamidyala、Soumya Ramu、Angela M. Kavanagh、Matthew A. Cooper

  DOI：10.1016/j.bmc.2014.05.054

  日期：2014.8

  An azide-functionalised analogue of the oxazolidinone antibiotic linezolid was synthesised and shown to retain antimicrobial activity. Using facile 'click' chemistry, this versatile intermediate can be further functionalised to explore antimicrobial structure-activity relationships or conjugated to fluorophores to generate fluorescent probes. Such probes can report bacteria and their location in a sample in real time. Modelling of the structures bound to the cognate 50S ribosome target demonstrates binding to the same site as linezolid is possible. The fluorescent probes were successfully used to image Gram-positive bacteria using confocal microscopy.
• J. Med. Chem. 1996, 39, 673-679
  作者：

  DOI：——

  日期：——
• Tetrahedron Lett. 1996, 37, 7937-7940
  作者：

  DOI：——

  日期：——
• Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections
  作者：Steven J. Brickner、Douglas K. Hutchinson、Michael R. Barbachyn、Peter R. Manninen、Debra A. Ulanowicz、Stuart A. Garmon、Kevin C. Grega、Susan K. Hendges、Dana S. Toops、Charles W. Ford、Gary E. Zurenko

  DOI：10.1021/jm9509556

  日期：1996.1.1

  Bacterial resistance development has become a very serious clinical problem for many classes of antibiotics. The 3-aryl-2-oxazolidinones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action which involves very early inhibition of bacterial protein synthesis. We have prepared two potent, synthetic oxazolidinones, U-100592 and U-100766, which are currently in clinical development for the treatment of serious multidrug-resistant Gram-positive bacterial infections caused by strains of staphylococci, streptococci, and enterococci. The in vitro and in vivo (po and iv) activities of U-100592 and U-100766 against representative strains are similar to those of vancomycin. U-100592 and U-100766 demonstrate potent in vitro activity against Mycobacterium tuberculosis. A novel and practical asymmetric synthesis of (5S)-(acetamidomethyl)-2-oxazolidinones has been developed and is employed for the synthesis of U-100592 and U-100766. This involves the reaction of N-lithioarylcarbamates with (R)-glycidyl butyrate, resulting in excellent yields and high enantiomeric purity of the intermediate (R)-5-(hydroxymethyl)-2-oxazolidinones,